heart failure, clinical management including infusion dose, duration, and concomitant drugs were recorded. Transthoracic 2-dimensional echocardiography was recorded on admission in 2,161 patients. The left ventricular ejection fraction (LVEF) was measured by the Teichholz method or area -length method. Changes in hemodynamic measurements and urine volume following carperitide infusion therapy were analyzed, as were changes in laboratory data. The global efficacy of carperitide infusion therapy in individual patients was evaluated by the attending physician based on changes in subjective symptoms: degree of dyspnea (0-3 scale assessment), palpitations, general weakness, chest oppression, cough or sputum and coldness of extremities, and physical findings; degree of lung rales (0-3 scale assessment), pretibial edema, cyanosis, and presence or absence of the third sound gallop, jugular venous dilation and hepatomegaly, and cardiovascular hemodynamics obtained by Swan-Ganz catheter method; heart rate, blood pressure (BP), right atrial pressure, pulmonary capillary pressure and cardiac output. The global efficacy was classified into 5 grades: markedly improved, improved, slightly improved, unchanged and exacerbated.
The term "efficacy" was defined as the percentage of patients assessed as "markedly improved" and "improved" in the total number of patients subjected to the efficacy analysis. The adverse event "BP lowering" was based on the judgement of the clinical investigators: BP <90 mmHg and/or lowering by more than 20 mmHg compared with the start of carperitide therapy.
The investigation was conducted according to the internal regulations for clinical study at each institution. Written or oral informed consent regarding medical treatment including carperitide therapy was obtained from each patient or the patient's family on admission.
Statistics
Median with 25-75th percentile was used to express the variation in percentage frequency if the distribution deviated from the standard normal distribution. In the Figs, frequency is expressed as proportions with 95% confidence limit. 7 Mean ± SD was used for parametric data. The 2 -test was used for the significance test of difference. To analyze the predictive values regulating the mortality rates, logistic multiple regression analysis was done. Statistical signifi- 
Results

Study Outline and Patient Characteristics
In total, 3,852 patients enrolled at 459 clinical institutions throughout Japan participated in this investigation, including those under intensive care unit, coronary care unit, emergency and critical care. Of these, 49 patients excluded because the drug was administered out of the specified period, 26 because of duplicate enrolment. Therefore, 3,777 were participated in the evaluation of safety. Futher, 3 patients excluded because the drug was not used in the approval dosage regimen (bolus injection) and 176 because of efficacy assessment unjudged. Therefore, 3,598 patients participated in the evaluation of efficacy (Fig 1) .
Of the 3,777 patients, 2,169 (57%) were male, and the median age was 73 years for 64-80 years of interquartile range ( Table 1 ). The patients were diagnosed as having either acute heart failure (61%) or acute decompensation of chronic heart failure (39%). The most common etiology of the heart failure was ischemic heart disease in 51%, consisting of acute myocardial infarction (AMI) in 16%, and other ischemic heart diseases including previous myocardial infarction in 35%, followed by valvular disease in 28% and hypertensive heart diseases in 16% (duplicate calculation). To assess the severity of acute heart failure, we used the Killip classification based on physical findings, the presence and area of audible moist rales in the lung, and the presence of the third heart sound, before treatment in 2,291 patients.
The mean LVEF was 47±17%, mean systolic and diastolic BPs were 132±29 and 71±17 mmHg, respectively, and the mean heart rate was 94±22 beats/min. The mean right atrial pressure, pulmonary capillary pressure, and cardiac output was 8.4±4.6 mmHg, 15.6±8.1 mmHg, and 4.3±1.5 L/min, respectively ( Table 1 ). The mean urine volume at baseline was 2.3 mL/min for 0.5-1.7 mL/min of interquartile range.
Carperitide Infusion
The mean infusion dose was determined as the sum of the products of infusion rate ( g·kg -1 ·min -1 ) and duration of infusion (min) at each dose level, divided by total infusion time (min). The mode of mean infusion dose was 0.1 g·kg -1 ·min -1 and the median was 0.085 g·kg -1 ·min -1 with an interquartile range of 0.05-0.10 g·kg -1 ·min -1 (range and % proportion to total patient number: ≤0.025 g· kg -1 ·min -1 8.1%, >0.025 to ≤0.50 g·kg -1 ·min -1 25.3%, >0.05 to ≤0.10 g·kg -1 ·min -1 48.3%, >0.10 to ≤0.15 g· kg -1 ·min -1 8.6%, >0.15 to ≤0.20 g·kg -1 ·min -1 8.4%, >0.20 g·kg -1 ·min -1 1.2%) The initial infusion rate was maintained in most patients throughout the treatment period; the median infusion time was 65 h for 22-142 h of the interquartile.
Factors Influencing Treatment Efficacy
Heart failure improved in 82% (total of "markedly improved", "improved" and "slightly improved") of the patients with carperitide therapy (Fig 2a) . The present investigation estimated the efficacy rate of carperitide infusion therapy as 55% for 95% confidence limit of 53-56%. Factors influencing the efficacy of carperitide therapy are shown in Table 2 . The efficacy was 54% in male and 55% in female. Because of the higher age of the present study's patients compared with previous clinical trials of carperi- Cr, creatinine. , and higher at 64% in patients with cardiomyopathy compared with those without (54%; p=0.0025), and those with valvular diseases (58% vs 53%, p=0.017), and also those with hypertensive heart disease (61% vs 54%, p=0.0036). The efficacy was significantly lower in patients with cardiogenic shock, namely Killip Class IV (49%) than in those with Killip Class II (60%) or III (62%) ( Table 2 ). The present investigation further indicated that the efficacy was significantly lower (47%) in patients with renal function disturbance (determined by serum creatinine concentration exceeding 2.0 mg/dl) than in those without this condition (56%).
Temporal Assessment of Efficacy of Carperitide Infusion
The median duration of infusion was 65 h with 22-142 h of the 25-75th percentiles, and 2,688 (72%) patients had an infusion for more than 24 h. The present real-world therapy investigation showed that improvement was observed in 69% of patients for whom the infusion was terminated at 24 h (efficacy rate, 38%), with an increase in the improvement rate to 83% (efficacy rate, 61%) in the next time period, 24-48 h, followed by a consistently higher rate of between 85 %and 88% (efficacy rate, 58-66%) up to 168 h Fig 2a) .
Adverse Events
Among the 3,777 patients, 1,055 adverse events were reported in 640 patients (16.94%) ( Table 3 ). The most frequently reported adverse events in the WHOART SystemOrgan Class 10 were those related to the cardiovascular system (9.64%, 364 patients), including BP lowering, followed by the urinary system (3.20%, 121 patients), including renal function disturbances, metabolic and nutritional disorders (3.07%, 116 patients), including serum electrolyte abnormalities, and liver and biliary system disorders (2.86%, 108 patients), including increased alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, -glutamyl transpeptidase or bilirubin. BP lowering was the most frequently reported adverse event (357 patients: 9.45%), and it occurred most frequently within 3 h of the start of infusion (in 5.57%; Fig 2b) . The total incidence within 24 h was 8.32%, followed by a decreased incidence for continued infusion between 0.15% and 0.69%; thus, approximately 70% of cases of BP lowering occurred within 6 h of starting the infusion of carperitide.
In order to determine the background factors influencing the incidence of the BP lowering, a comparison was made of the baseline characteristics of the patients. The incidence was higher in patients aged 65 years or more (10.27%) than in younger patients (7.69%), higher in those with AMI than in those without it (11.95% vs 9.13%) and higher in those with a LVEF <35% (12.08% vs 8.45%); no significant difference was observed between genders, or those with and without diabetes mellitus.
Occurrence of BP lowering was not dose-related: it was highest at 10.8% in the dose group 0.025-0.05 g·kg -1 · min -1 , which was most frequently used, followed by the group 0.05-0.1 at 10.4%, and at approximately 7% in the other groups. The hemodynamic parameters before treatment in patients with and without developing BP lowering were 130±28 vs 132±29 mmHg for systolic BP, 70±16 vs 71±17 mmHg for diastolic BP, and 97±24 vs 94±22 for heart rate (all not significant).
Recovery From BP Lowering
Major treatments for the BP lowering reported in the 
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present investigation were discontinuation of carperitide infusion, reduction of dose, fluid loading, vasopressor injection or a combination of these treatments (Fig 3) . Carperitide infusion was discontinued in 45.2% of cases, and 36.3% received an injection of vasopressor. Of the patients who had these treatments, 94% recovered or improved satisfactorily without any other special treatment. Recovery from BP lowering was attained within 3 h after the treatments in approximately half of the 94% of patients affected.
Mortality
Mortality during the treatment period of acute heart failure including up to 7 days post-infusion was 11.4%. Mortality was higher in older patients, particularly those over 85 years old, in patients with LVEF <35%, those with serum creatinine concentration ≥2.0 mg/dl, and in those with a lower initial systolic BP, particularly <90 mmHg (Fig 4) . Mortality was higher with a higher infusion dose and the use of positive inotropic agents compared to those without it. Logistic regression analysis performed to find predictors of the mortality rate in 1,226 patients with the full set of data for age, Killip Class, initial systolic BP, LVEF, serum creatinine concentration, treatment with vasopressor and infusion dose revealed that the maximum likelihood estimates of age (p<0.0001), Killip Class (p<0.0001), systolic BP (p=0.0003), serum creatinine (p<0.0001), and use of vasopressor (p=0.0015) were highly significant.
Discussion
Patient Characteristics
The cohort of this surveillance investigation comprised relatively older patients with nearly equal numbers of both genders. Fifty-one percent of the patients had coronary artery diseases. More than half (58%) of the patients received a lower infusion dose of carperitide than the approved dose and a variety of infusion duration these seemed to reflect the management of acute heart failure without any restrictions; that is, the real world of therapy rather than a clinical trial. The median age of the patients in our study cohort, 73 with an interquartile range of 64-80, was obviously different to the latest clinical investigation, a randomized controlled trial on nesiritide (B-type natriuretic peptide: BNP) in the management of decompensated congestive heart failure, in which the average age of the patients ranged from 54 to 65 years. [11] [12] [13] Epidemiological investigations have revealed that the prevalence of congestive heart failure increases proportionally with age, with a particularly remarkable increase in the group of patients aged ≥60 years. [14] [15] [16] The present investigation included 16% of the patients classified as Killip Class I, which might reflect the inclusion of the patients with symptom-less heart failure for whom carperitide was used with the expectation of diuresis and/or cardio-renal protection, [17] [18] [19] [20] [21] [22] in the real-world therapy of heart failure.
Patient Characteristics Affecting Treatment Efficacy
Lower efficacy in patients with AMI seems to reflect the different pathophysiology that frequently occurs with the limitation of compensatory mechanisms following sudden onset of the disease. The efficacy was lower at 49% in patients with cardiogenic shock (Killip Class IV) compared with those in Class II (60%) or III (62%).
On the other hand, the efficacy was significantly higher in patients with cardiomyopathy, valvular diseases, and hypertensive heart disease in which their pathophysiological condition was classified as decompensation of chronic heart failure, and the circulating blood volume was increased as one of the important compensatory mechanisms.
In such excessive preload conditions, the efficacy of carperitide would be mostly demonstrated in dilation of the venous capacitance vessels as well as reducing body fluid by its diuretic action and consequent removal of the pulmonary congestion. 2 
BP Lowering
The mechanism of the BP lowering after carperitide infusion is probably attributable to its main pharmacological actions, vasodilation and natriuresis. In some patients with normovolemic or latent hypovolemic conditions, such as aged patients with Killip Class I AMI, the BP may be lowered because of excess reduction in preload following vasodilation. The occurrence of BP lowering is also related to the severity of heart failure, in which right ventricular failure complicated by left-sided ventricular failure will result in a critical condition that is both a preload-and heart rate-dependent state. [23] [24] [25] [26] Most cases recovered satisfactorily or improved with standard treatments for hypotension: fluid loading, infusion of vasopressors, with or without discontinuation of the carperitide infusion.
Analysis of Efficacy During Infusion and the Magnitude of the "Slightly Improved" Assessment for Efficacy
In this study the global efficacy of 55% was the rate of the upper 2 grades of the attending physician's assessment, "markedly improved" and "improved", as described in the Methods section. This summary of the efficacy is expressed according to the standards used for clinical trials conducted for Japan's Manufacture (Import) Approval of Drugs. In fact, the number of patients assessed as "slightly improved" which might be included in the category of "efficacious" in other clinical studies, [14] [15] [16] was significant and could not be neglected in our investigation; 27% of patients were assessed "slightly improved".
Efficacy Assessment in the Real World of Therapy
Dose-response efficacy was not observed in the present real-world therapy analysis, although a proportional correlation had been shown in a clinical trial for the titration study in terms of a dose-dependent hemodynamic improvement. 27 In the real world of therapy, the dose-response efficacy of carperitide was not always observed because the cohort comprised a wide window of enrolment without previous equalization of patient number/backgrounds and complex concomitant medical treatments among the dose levels, which were strictly controlled in the clinical trials for the titration studies. As described earlier, the present investigation has revealed the influence of pathophysiological differences in the underlying diseases on the efficacy of carperitide therapy; that is, efficacy is lower in patients with AMI, especially those with cardiogenic shock (Killip Class IV), and higher in patients with decompensated chronic heart failure. The present results further indicated that the efficacy is significantly lower in patients with renal function disturbance.
The number of patients on infusion of carperitide diminished successively almost log-linearly over time in this cohort of patients and the reasons for the termination or continuation of infusion of the drug seem to be multifactorial: termination or change to another drug because of satisfactory improvement, experience of adverse events, or unsatisfactory or no improvement or exacerbation of symptoms. Such factors or a combination of these will influence the efficacy judgment and the termination of therapy. On the other hand, the infusion therapy was continued for maintenance of the improved condition as long as the drug exhibited efficacy, or in the expectation of improvement of the clinical condition from a compromised or partly improved state. These were not always distinguishable in this surveillance. However, the study did clarify that the majority of episodes necessitating the discontinuation of carperitide infusion appeared within 3 h of starting the infusion.
Temporal analysis of the efficacy revealed that sufficient efficacy was not achieved in the patients whose infusion was terminated within 24 h, but became stable thereafter in those who underwent infusion therapy for up to 168 h or more. Previous studies of carperitide have demonstrated that significant hemodynamic improvements, including lowering of the pulmonary capillary wedge pressure and right atrial pressure, were maintained for 7 days of infusion of carperitide, associated with an increase in the cardiac index. 28 
Mortality
Logistic regression analysis in the present real-world analysis revealed that factors predicting mortality during 7 days of follow-up were age, Killip Class, renal function disturbance, initial BP and use of vasopressors. These findings were consistent with previous reports regarding the use of intravenous vasopressor or inotropic agents in patients with acute or refractory heart failure. [29] [30] [31] It is unclear that additional intravenous vasopressor infusion would outweigh the risks of increased ventricular arrhythmias and ischemia associated with increased myocardial oxygen consumption. Two small randomized studies showed higher mortality with dobutamine infusion. 29, 30 The negative results of the OPTIME trial of 48-h infusion of milrinone might also be extrapolated to indicate a likelihood of aggravation with routine use of vasopressors or inotropics for the management of heart failure. 31 
Clinical Implication and Study Limitations
The present prospective investigation of real-world therapy revealed that 82% of the patients were assessed as improved by the treatment and the clinical efficacy increased gradually even at 24 h and reached a stable rate of improvement at 72 h after the start of infusion, indicating that the finally assessment of efficacy was based on its success/failure in managing acute heart failure in general throughout the treatment period. Unlike controlled clinical trials, the dose-related pharmacological property was not always shown in this real-world investigation; the efficacy was assumed to be affected by the severity of heart failure or concomitant medication including vasopressor or positive inotropic drugs. As the most frequent adverse event, BP lowering appeared within the first 3 h of infusion, and the majority of patients recovered or improved within 3 h of being given standard treatment. Analysis of the prognostic factors regarding the patients treated with carperitide revealed that advanced age, severity of heart failure, renal function disturbances, low initial systolic BP and use of vasopressors are predictors significantly correlated with mortality. Based on these findings, a minute strategy will be established for carperitide therapy within the strata of patient characteristics that may predict the prognosis.
